🇺🇸 FDA
Patent

US 10172937

Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10172937 (Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies) held by Five Prime Therapeutics, Inc. expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545